Download PDF
Aktuelle Urol 2014; 45(1): 55-65
DOI: 10.1055/s-0033-1360281
Fortbildung
Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Entwicklungen in der medikamentösen Therapie des fortgeschrittenen Blasenkarzinoms

Current Developments in the Medical Treatment of Advanced Urothelial Carcinoma of the Bladder
S. C. Schmid
Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München
,
J. E. Gschwend
Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München
,
M. Retz
Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, München
,
für die Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft (AUO) › Author Affiliations
Further Information

Publication History

Publication Date:
05 February 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die medikamentöse Therapie des fortgeschrittenen Urothelkarzinoms umfasst sowohl die perioperative Therapie als auch die palliative systemische Chemotherapie in fortgeschrittenen Stadien. Der Artikel soll einen Überblick über wesentliche Entwicklungen und klinische Studien der letzten 2 Jahre geben. Dazu wurde eine Literaturrecherche bei MEDLINE/PubMed durchgeführt sowie die Abstracts der Kongresse ASCO, GU-ASCO, EAU und AUA analysiert. Der Nutzen der perioperativen Chemotherapie wird weiter bestätigt. In der Therapie des metastasierten Urothelkarzinoms bleibt Gemcitabin/Cisplatin der Standard, während eine Therapie mit Targettherapeutika bisher zu keinen wesentlichen Erfolgen geführt hat.

Abstract

Medical treatment of advanced urothelial carcinoma of the bladder consists of perioperative treatments as well as palliative chemotherapy in advanced stages. This article focuses on important clinical trials and developments of the last two years, with a review of literature and proceedings of the relevant meetings (ASCO, GU-ASCO, EAU, AUA). The general benefit of perioperative chemotherapy is confirmed. Chemotherapy with Gemcitabin/Cisplatin remains the therapy of choice in the palliative setting. So far, targeted therapies did not show convincing results.

Key words

Blasenkarzinom - Urothelkarzinom - medikamentöse Tumortherapie - AUO - Chemotherapie - Onkologie

Key words

bladder cancer - urothelial carcinoma - chemotherapy - oncology - AUO
 

  • Literatur

  • 1 Hautmann RE, Gschwend JE, de Petriconi RC et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176: 486-492 discussion 491–492
    CrossrefPubMedGoogle Scholar
  • 2 Advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-205 discussion 205–206
    CrossrefPubMedGoogle Scholar
  • 3 Kitamura H, Tsukamoto T, Masumori N et al. Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209. J Clin Oncol 2013; 31 (Suppl.) abstract 4526
    PubMedGoogle Scholar
  • 4 Griffiths G, Hall R, Sylvester R et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177
    CrossrefPubMedGoogle Scholar
  • 5 Fairey AS, Daneshmand S, Quinn D et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol 2013; 31: 1737-1743
    PubMedGoogle Scholar
  • 6 Pal SK, Ruel NH, Wilson TG et al. Retrospective analysis of clinical outcomes with neoadjuvant Cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012; 10: 246-250
    CrossrefPubMedGoogle Scholar
  • 7 Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513
    CrossrefPubMedGoogle Scholar
  • 8 Mertens LS, Meijer RP, Kerst JM et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer – a reasonable alternative for cisplatin unfit patients?. J Urol 2012; 188: 1108-1113
    CrossrefPubMedGoogle Scholar
  • 9 Koie T, Ohyama C, Hashimoto Y et al. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol 2012; DOI: 10.1007/s10147-012-0447-z.
    PubMedGoogle Scholar
  • 10 Scosyrev E, Messing EM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?. BJU Int 2011; 108: 700
    PubMedGoogle Scholar
  • 11 Advanced bladder cancer (ABC) meta-analysis collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48: 189-199 discussion 199–201
    CrossrefPubMedGoogle Scholar
  • 12 Paz-Ares L, Solsona E, Esteban E et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2010; 28 (Suppl.) Abstr. LBA4518
    CrossrefPubMedGoogle Scholar
  • 13 Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2012; 23: 695-700
    CrossrefPubMedGoogle Scholar
  • 14 Lehmann J, Kuehn M, Fischer C et al. Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). J Clin Oncol 2013; 31 (Suppl. 06) abstract 250
    PubMedGoogle Scholar
  • 15 Sternberg CN, Bellmunt J, Sonpavde G et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013; 63: 58-66
    CrossrefPubMedGoogle Scholar
  • 16 Tjokrowidjaja A, Lee C, Stockler MR. Does chemotherapy improve survival in muscle-invasive bladder cancer (MIBC)? A systematic review and meta-analysis (MA) of randomized controlled trials (RCT). J Clin Oncol 2013; 31 (Suppl.) Abstr. 4544
    CrossrefPubMedGoogle Scholar
  • 17 von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608
    CrossrefPubMedGoogle Scholar
  • 18 Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113
    CrossrefPubMedGoogle Scholar
  • 19 Urakami S, Fujii Y, Yamamoto S et al. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urol Oncol 2013; DOI: 10.1016/j.urolonc.2013.01.007.
    PubMedGoogle Scholar
  • 20 Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr Opin Urol 2009; 19: 533-539
    CrossrefPubMedGoogle Scholar
  • 21 Sonpavde G, Sternberg CN, Rosenberg JE et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010; 11: 861-870
    CrossrefPubMedGoogle Scholar
  • 22 Grivas P, Agarwal N, Siefker-Radtke AO et al. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). J Clin Oncol 2012; 30 (Suppl.) Abstr. 4506
    PubMedGoogle Scholar
  • 23 Hahn NM, Stadler WM, Zon RT et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75. J Clin Oncol 2011; 29: 1525-1530
    CrossrefPubMedGoogle Scholar
  • 24 Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000; 5: 224-237
    Google Scholar
  • 25 De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199
    CrossrefPubMedGoogle Scholar
  • 26 Pagliaro LC, Munsell MF, Harris D et al. Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study. J Clin Oncol 2013; 31 (Suppl.) abstract 4528
    PubMedGoogle Scholar
  • 27 Necchi A, Zaffaroni N, Mariani L et al. Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC). J Clin Oncol 2012; 30 (Suppl.) Abstr. 4507
    PubMedGoogle Scholar
  • 28 Seront E, Rottey S, Sautois B et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23: 2663-2670
    CrossrefPubMedGoogle Scholar
  • 29 Niegisch G, Retz M, Thalgott MK et al. Second-line treatment of advanced urothelial cancer with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09). J Clin Oncol 2012; 30 (Suppl.) Abstr. 4590
    PubMedGoogle Scholar
  • 30 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Qualität der pädiatrisch-hämatologisch-onkologischen Versorgung. IQWiG-Berichte. Köln: IQWiG; 2009
    Google Scholar